Abstract: The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD 138, HER2 and CD24. Further, the invention provides pharmaceutical compositions comprising these CAR T-cells and their use in treatment of cancer, in particular, ovarian cancer, DNA constructs encoding said CARs and methods for preparation of T-cells expressing said CARs.

Abstract: The present invention discloses chimeric antigen receptors that specifically recognize and bind to Sialyl Tn carbohydrate antigen with high specificity and selectivity. The invention further provides lymphocytic cells, such as T cells, comprising said CARs, compositions comprising said cells or CARs as well as uses thereof.

Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 scFv and the second CAR anti-CD138 scFv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.

Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.

Abstract: Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising culturing T cells in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells. Also provided are cell cultures, isolated T cells and uses of same.

Abstract: A method of generating a population of genetically modified veto cells is disclosed. The method comprising: (a) providing a population of cells comprising T cells, the T cells comprising at least 40% memory CD8+ T cells; (b) culturing the population of cells comprising T cells with an antigen or antigens under conditions which allow enrichment of tolerance-inducing antigen-specific cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being depleted of graft versus host (GVH) reactivity; and (c) transducing the cells with a polynucleotide encoding a heterologous cell surface receptor comprising a T cell receptor signaling module, thereby generating the population of genetically modified veto cells.

Abstract: The present invention discloses a fusion protein comprising a vesicular stomatitis virus envelope glycoprotein (VSVG) extracellular domain or a fragment or an analog thereof linked to a polypeptide comprising an antigen binding domain specific to cluster of differentiation 3 (CD3). The application also discloses pseudotyped viruses comprising the fusion protein and pseudotyped viruses encoding for a chimeric antigen receptor (CAR) or T-cell receptor pseudotyped in which the receptor is expressed under a CD3 promoter. Pseudotyped viruses combining these properties are encompassed as well. The application further discloses use of these pseudotyped viruses and method of producing these pseudotyped viruses.

Abstract: The present invention discloses chimeric antigen receptors that specifically recognize and bind to SLe A carbohydrate antigen with high specificity and selectivity. The invention further provides lymphocytic cells, such as T cells, comprising said CARs, compositions comprising said cells or CARs as well as uses thereof.

Abstract: The present invention provides extracellular vesicles (EVs) derived from T-cells expressing chimeric antigen receptors (CAR) specifically activated with an antigen to which the CAR bind specifically, pharmaceutical compositions comprising these vesicles as well as their use in treating cancer. In particular the present invention exemplifies EVs derived from activated T-cells expressing CAR that bind specifically to HER2 cancer antigen, pharmaceutical composition comprising these EVs and their use in treating a cancer overexpressing HER2, such as ovarian cancer and breast cancer.

Abstract: The present invention provides T-cells modified to express at least two chimeric antigen receptors, wherein one of the CARs binds specifically to an antigen selected from CD138, HER2 and CD24 and another CAR binds specifically a different antigen selected from CD138, HER2 and CD24. Further, the invention provides pharmaceutical compositions comprising these CAR T-cells and their use in treatment of cancer, in particular, ovarian cancer, DNA constructs encoding said CARs and methods for preparation of T-cells expressing said CARs.

Abstract: The present invention provides T-cells expressing at least two different chimeric antigen receptors, wherein one of the CARs binds specifically to CD138 and another CAR binds specifically to CD38. In particular, the present invention provides T-cells expressing two different CARs, when one CAR comprises anti-CD138 sc Fv and the second CAR anti-CD138 sc Fv. Further, the invention provides a pharmaceutical composition comprising these dual CAR T-cells and their use in treatment of cancer, in particular multiple myeloma, and methods for preparation of these cells.

Abstract: Methods of culturing T cells are provided. Accordingly there is provided a method of culturing T cells comprising culturing T cells in the presence of a T cell stimulator, an exogenous CCL21 and an exogenous ICAM1, thereby culturing the T cells. Also provided are cell cultures, isolated T cells and uses of same.

Abstract: A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.

Abstract: A method of treating a disease, such as cancer, by administering to a subject in need of such treatment an effective amount of allogeneic T cells with a MHC unrestricted chimeric receptor short time after partial lymphodepletion. The method also comprises administering one or more agents that delay egression of the allogeneic T cells from lymph nodes of said subject during adoptive transfer of said allogeneic T cells to the subject by trapping the T cells in the lymph nodes.

Abstract: Isolated peptides of 13-30 amino acids comprising 5-9 consecutive repeats of the amino acid pair Alanine-Leucine or Alanine-Valine are provided. The peptides further comprise a stretch of 1-3 Lysine residues present at least at one of the peptide's termini, wherein the only Lysine residue in the isolated peptide is present at the stretch of 1-3 Lysine residues. Pharmaceutical compositions comprising same, methods of treating inflammatory conditions and allergic reactions, as well as methods of neutralizing the activity of lypopolysaccharides are also provided.

Abstract: Anti-inflammatory peptides and pharmaceutical compositions including lysine, alanine, leucine and/or valine for treating inflammatory conditions and uses thereof. Anti-inflammatory peptides for treating IgE-mediated allergies and inflammatory conditions caused by a microbial infection including but not limited to sepsis.

Abstract: Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.

Abstract: Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.

Abstract: Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.

Abstract: Chimeric receptor genes suitable for endowing lymphocytes with antibody-type specificity include a first gene segment encoding a single-chain Fv domain of a specific antibody and a second gene segment encoding all or part of the transmembrane and cytoplasmic domains, and optionally the extracellular domain, of an immune cell-triggering molecule. The chimeric receptor gene, when transfected to immune cells, expresses the antibody-recognition site and the immune cell-triggering moiety into one continuous chain. The transformed lymphocytes are useful in therapeutic treatment methods.